Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

GlaxoSmithKline : Dr Hal Barron appointed Chief Scientific Officer and President, Research & Development, GSK

share with twitter share with LinkedIn share with facebook
share via e-mail
11/10/2017 | 03:31pm CEST

GlaxoSmithKline plc on November 8 announced that Dr Hal Barron has been appointed Chief Scientific Officer and President, R&D, GSK. He has also been appointed as an Executive Director to the GSK Board. Dr Barron will assume his new role and join the Board on 1 January 2018.

Dr Barron is currently President R&D at Calico (California Life Sciences LLC), an Alphabet-funded company that uses advanced technologies to increase understanding of lifespan biology. Prior to joining Calico, Dr Barron was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was Senior Vice President Development and Chief Medical Officer, according to GlaxoSmithKline.

Emma Walmsley, CEO, GSK said: Scientific innovation must be at the heart of GSK and with the appointment of Hal, we are bringing one of the worlds foremost R&D leaders to the company.

Hal has exceptional experience and a strong track record of developing significant new medicines from his time at Roche and Genentech; whilst at Calico he has helped build a research organisation that uses cutting-edge technologies in drug discovery and development. He is also very well known for his integrity, for being a clinician who is committed to always doing the best he can for patients and for building exceptional teams.

The fusion of science and technology is fast transforming pharmaceuticals R&D. With Hal, we have a new R&D leader who will drive the changes and choices we need to make to be successful in this new environment, and as we look to build the next wave of growth for the company.

Philip Hampton, Chairman, GSK, said: We are delighted that Hal will be joining GSK and look forward to welcoming him to the Board. He is a highly respected clinician-scientist with a proven ability to generate value for shareholders and his appointment reflects the Boards commitment to investing in research and development.

Dr Barron said, I am honoured to have been chosen for this important position especially given the companys renewed focus on discovering and developing transformational new medicines. GSK is a company with a rich history of innovation, with many talented scientists who care deeply about translating great science into therapies that make a meaningful difference for patients. I believe there is a significant opportunity to accelerate this effort and am looking forward to joining Emma and the team on this mission.

During his time at Genentech and Roche, Dr Barron oversaw the development of Xolair (Asthma), Avastin (multiple tumour types), Tarceva (Lung Cancer), Lucentis (AMD), Actemra (Rheumatology), Zelboraf and Erivedge (Melanoma), Perjeta and Kadcyla (Breast Cancer), as well as Gazyva (CLL). He has overseen pioneering work in oncology, personalised medicine and has led teams across the USA, Europe and Asia.

Prior to joining Genentech as a clinical scientist in 1996, Dr Barron received his Bachelor of Science in physics from Washington University in St. Louis, his medical degree from Yale University, and completed his training in Cardiology and Internal Medicine at the University of California San Francisco.

Dr Barrons academic positions include adjunct professor at the University of California, San Francisco. He has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals.

Dr Barron will be based in the US, while operating from offices in both San Francisco and Stevenage in the UK. The new office presence in San Francisco will be focused on business development for R&D.

(c) 2017 Palestine News & Information Agency (WAFA). All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE 3.07% 1531.4 Delayed Quote.15.80%
ROCHE HOLDING LTD. 0.04% 235.15 Delayed Quote.-4.60%
share with twitter share with LinkedIn share with facebook
share via e-mail
01:21pGLAXOSMITHKLINE : The BMJ Questions Transparency of Information Surrounding Safe..
09/21GLAXOSMITHKLINE : GSK and Tres Cantos Open Lab Foundation announce additional £5..
09/21GLAXOSMITHKLINE : Philly's U.S. attorney pursuing corporate espionage and white ..
09/21GlaxoSmithKline, Innoviva Get Positive CHMP Opinion on Expanded COPD Indicati..
09/21GLAXOSMITHKLINE : CHMP recommends expansion of Trelegy COPD label
09/21GLAXOSMITHKLINE : MILITARY $5.09 Million Federal Contract Awarded to GlaxoSmithK..
09/20GLAXOSMITHKLINE : New HIV/AIDS Findings Reported from GlaxoSmithKline plc (Bioeq..
09/20GLAXOSMITHKLINE : Findings from GlaxoSmithKline plc in the Area of Prostatic Hyp..
09/20MANAGEMENT TRACKS : GSK adds Corsico, Enzmann to chair CHMP
09/20Nestle aims to shed skin unit to focus on food, nutrition
More news
News from SeekingAlpha
09/21European advisory group backs expanded use for Glaxo's Trelegy Ellipta 
09/20Entasis Therapeutics Readies $75 Million IPO Plan 
09/18Glaxo fielding multiple bids for Indian Horlicks unit 
09/18YOUR DAILY PHARMA SCOOP : Alnylam Regains, Karyopharm Positive, Teva Approved 
09/17GSK's 2-Drug Combo For HIV Could Threaten Gilead 
Financials (GBP)
Sales 2018 30 372 M
EBIT 2018 8 143 M
Net income 2018 3 409 M
Debt 2018 20 469 M
Yield 2018 5,22%
P/E ratio 2018 21,96
P/E ratio 2019 17,16
EV / Sales 2018 3,17x
EV / Sales 2019 3,06x
Capitalization 75 962 M
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 16,5  GBP
Spread / Average Target 7,5%
EPS Revisions
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Paul Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.62%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
MERCK AND COMPANY25.79%189 092